Low-cost generic drugs under the President's Emergency Plan for AIDS Relief drove down treatment cost; more are needed

Health Affairs

Volumn 31, Issue 7, 2012, Pages 1429-1438

  Venkatesh, Kartik K ^a   Mayer, Kenneth H ^b   Carpenter, Charles C J ^a  

^a BROWN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GENERIC DRUG; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; QUALITY CONTROL; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG RESISTANCE, VIRAL; DRUGS, GENERIC; EMERGENCIES; HUMANS; INTERNATIONAL COOPERATION; RELIEF WORK; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 84866274606     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0210     Document Type: Article

References (55)

1. Institute of Medicine. PEPFAR implementation: progress and promise. Washington (DC): National Academies Press; 2007.
2. President's Emergency Plan for AIDS Relief. About PEPFAR [Internet]. Washington (DC): PEPFAR; [cited 2012 Jun 5]. Available from: http://www.pepfar.gov/about/index.htm
3. AVERT. PEPFAR and the Global Health Initiative [Internet]. Horsham, West Sussex, UK: AVERT; [cited 2012 Jun 25]. Available from: http://www.avert.org/pepfar.htm#contentTable0
4. Bristol N. US Senate passes new PEPFAR bill. Lancet. 2008;372: 277-8.
5. President's Emergency Plan for AIDS Relief. Latest results [Internet]. Washington (DC): PEPFAR; [cited 2012 Jun 5]. Available from: http://www.pepfar.gov/results/index.htm
6. Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes. Ann Intern Med. 2009;150(10):688-95.
7. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington (DC): Department of Health and Human Services; [last updated 2012 Mar 27; cited 2012 Jun 5]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand.AdolescentGL.pdf
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision [Internet]. Geneva: WHO; 2010 [cited 2012 Jun 5]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf
9. Kumarasamy N. Generic antiretroviral drugs-will they be the answer to HIV in the developing world? Lancet. 2004;364:3-4.
10. Holmes C, Coggin W, Jamieson D, Mihm H, Granich R, Savio P, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010; 304(3):313-20.
11. Bartlett JA, Muro EP. Generic and branded drugs for the treatment of people living with HIV/AIDS. J Int Assoc Physicians AIDS Care (Chic). 2007;6(1):15-23.
12. Food and Drug Administration. International Programs: President's Emergency Plan for AIDS Relief: approved and tentatively approved antiretrovirals in association with the President's Emergency Plan [Internet]. Silver Spring (MD): FDA; [last updated 2012 May 31; cited 2012 Jun 5]. Available from: http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm
13. Supply chain heroes. LogisticsWeek [serial on the Internet]. 2011 May 12 [cited 2012 Jun 5]. Available from: http://logisticsweek.com/news//2011/05/supply-chain-heroes/
14. Bristol N. Tobias' dual role heightens concern over US humanitarian aid. Lancet. 2006;367:1131-2.
15. World Health Organization. Prequalification programme [Internet]. Geneva: WHO; 2011 [cited 2012 Jun 5]. Available from: http://apps.who.int/prequal/
16. Orsi F, D'Almeida C, Hasenclever L, Camara M, Tigre P, Coriat B. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges. AIDS. 2007;21(15):1997-2003.
17. Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, et al. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health. 2010;6:9.
18. SCMS. About us [Internet]. Arlington (VA): Supply Chain Management System; [cited 2012 Jun 5]. Available from: http://scms.pfscm.org/scms/about
19. Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability, and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003; 17(15):2267-9.
20. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004; 264:29-34.
21. Kumarasamy N, Solomon S, Chaguturu SK, Cecelia AJ, Vallabhaneni S, Flanigan TP, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis. 2005;41:1525-8.
22. President's Emergency Plan for AIDS Relief. Report on costs of treatment in the President's Emergency Plan for AIDS Relief (PEPFAR) [Internet]. Washington (DC): PEPFAR; 2012 Feb [cited 2012 Jun 5]. Available from: http://www.pepfar.gov/documents/organization/188493.pdf
23. President's Emergency Plan for AIDS Relief. PEPFAR secures cost savings and low prices on lifesaving medicines for developing countries [Internet]. Washington (DC): PEPFAR; [cited 2012 Jun 5]. Available from: http://2006-2009.pepfar.gov/press/83466.htm
24. Menzies N, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25(14): 1753-60.
25. Padian N, Holmes CB, McCoy SI, Lyerla R, Bouey PD, Goosby EP. Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR). J Acquir Immune Defic Syndr. 2011;56(3):199-203.
26. Cohen M, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505.
27. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008; 47(5):712-22.
28. Gallant J. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2007;44(3):453-5.
29. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008; 13(Suppl 2):15-23.
30. Mann M, Diero L, Kemboi E, Mambo F, Injera W, DeLong A, et al. Unplanned antiretroviral treatment interruptions induced by the Kenyan post-election crisis are associated with HIV virologic failure. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; 2012 Mar 5-8; Seattle,WA.
31. Marconi V, Sunpath H, Li Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46: 1589-97.
32. Orsi F, d'Almeida C. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries. Curr Opin HIV AIDS. 2010;5(3):237-41.
33. Ferguson IF. World Trade Organization negotiations: the Doha development agenda [Internet]. Washington (DC): Congressional Research Service; [updated 2008 Jan 18; cited 2012 Jun 6]. (CRS Report for Congress No. RL32060). Available from: http://www.nationalaglawcenter.org/assets/crs/RL32060.pdf
34. Cohen-Kohler JC, Forman L, Lipkus N. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards. Health Econ Policy Law. 2008;3: 229-56.
35. Venkatesh K, Kumarasamy N, Mayer KH. Indian manufacture of new generic antiretrovirals: implications for global access to anti-HIV drugs. Futur HIV Ther. 2010;4(1):1-4.
36. Havlir D, Hammer SM. Patents versus patients? Antiretroviral therapy in India. N Engl J Med. 2005;353(8): 749-51.
37. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-9.
38. Filler SJ, Berruti AA, Menzies N, Berzon R, Ellerbrock TV, Ferris R, et al. Characteristics of HIV care and treatment in PEPFAR-supported sites. J Acquir Immune Defic Syndr. 2011;57(1):e1-6.
39. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49(2):306-9.
40. Rawizza H, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283-90.
41. Denny C, Emanuel EJ. US health aid beyond PEPFAR: the mother and child campaign. JAMA. 2008; 300(17):2048-51.
42. Coggin W, Ryan CA, Holmes CB. Role of the US President's Emergency Plan for AIDS Relief in responding to tuberculosis and HIV coinfection. Clin Infect Dis. 2010; 50(Suppl 3):S255-9.
43. World Health Organization. Task shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines [Internet]. Geneva: WHO; 2008 [cited 2012 Jun 6]. Available from: http://www.who.int/health systems/TTR-TaskShifting.pdf
44. Dybul M. Lessons learned from PEPFAR. J Acquir Immune Defic Syndr. 2009;52(Suppl 1):S12-3.
45. Larson E, O'Bra H, Brown JW, Mbengashe T, Klausner JD. Supporting the massive scale-up of antiretroviral therapy: the evolution of PEPFAR-supported treatment facilities in South Africa, 2005-2009. BMC Public Health. 2012;12:173.
46. Walensky R, Kuritzkes DR. The impact of the President's Emergency Plan for AIDS Relief (PEPFAR) beyond HIV and why it remains essential. Clin Infect Dis. 2010;50(2): 272-5.
47. Appointment of PEPFAR head should be merit based. Lancet. 2009;373(9661):354.
48. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic: 2010 [Internet]. Geneva: UNAIDS; 2010 [cited 2012 Jun 15]. Available from: http://www.unaids.org/global report/documents/20101123_ GlobalReport_full_en.pdf
49. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report. Geneva: WHO; 2007.
50. Brown D. Obama proposes helping more people get access to AIDS drugs. Washington Post. 2011 Dec 1.
51. Kaiser Family Foundation. US funding for the Global Health Initiative (GHI): the president's FY 2013 budget request [Internet]. Menlo Park (CA): KFF; 2012 Feb [cited 2012 Jun 15]. (Fact Sheet). Available from: http://www.kff.org/globalhealth/upload/8160-02.pdf
52. World Health Organization. Antiretroviral therapy (ART) coverage among all age groups [Internet]. Geneva: WHO; [cited 2012 Jun 15]. Available from: http://www.who.int/gho/hiv/epidemic_response/ART_text/en/index.html.
53. Wirtz V, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S. Factors influencing global antiretroviral procurement prices. BMC Public Health. 2009;9(Suppl 1):S6.
54. Bermudez J, 't Hoen E. The UNITAID patent pool initiative: bringing patents together for the common good. Open AIDS J. 2010;4:37-40.
55. Mayer K, Venkatesh KK. Antiretroviral therapy for HIV prevention: current status and future prospects. Am J Public Health. 2010;100(10): 1867-76.